FIGURE

Fig. 7

ID

ZDB-FIG-220719-67

Publication

Bär et al., 2022 - Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

Other Figures

All Figure Page

Back to All Figure Page

Fig. 7

Quantification of the expression of selected HDAC proteins. HepG2 and Huh7 cells were treated for 24 h with either solvent (Ctrl), bb at IC₅₀ (0.6 µM), bb at two-fold IC₅₀ (1.2 µM) or vs. at two-fold IC₅₀ (4.0 µM). Western blotting was used to measure protein expression, using tubulin as loading control. (A) HDAC1 expression in Hep2G and Huh7 cells. (B) HDAC2 expression in Hep2G and Huh7 cells. (C) HDAC4 expression in Hep2G and Huh7 cells. ^**P<0.01 vs. ctrl. (D) HDAC6 expression in Hep2G and Huh7 cells. Corresponding representative western blotting images are provided in Fig. S2. n=3 per group. One-way ANOVA with Tukey's post hoc test was used to test for significance. HDAC, histone deacetylase; Ctrl,. control; bb, broxbam; vs, vorinostat.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Oncol.